Tango Therapeutics (NASDAQ:TNGX – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Tango Therapeutics to related companies based on the strength of its risk, earnings, valuation, profitability, dividends, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Tango Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tango Therapeutics | $62.38 million | -$101.59 million | -17.64 |
| Tango Therapeutics Competitors | $690.32 million | $9.48 million | -18.32 |
Tango Therapeutics’ competitors have higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Tango Therapeutics and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tango Therapeutics | 2 | 2 | 13 | 0 | 2.65 |
| Tango Therapeutics Competitors | 9924 | 15317 | 45695 | 1603 | 2.54 |
Tango Therapeutics presently has a consensus target price of $45.54, suggesting a potential upside of 88.41%. As a group, “Biotechnology” companies have a potential upside of 131.37%. Given Tango Therapeutics’ competitors higher possible upside, analysts plainly believe Tango Therapeutics has less favorable growth aspects than its competitors.
Profitability
This table compares Tango Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tango Therapeutics | N/A | -30.34% | -28.28% |
| Tango Therapeutics Competitors | -12,319.70% | -407.93% | -30.95% |
Insider and Institutional Ownership
79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Tango Therapeutics beats its competitors on 7 of the 12 factors compared.
Tango Therapeutics Company Profile
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
